University of Washington

University of Montana

Guilloteau, Nicolas

Brian Buttrick

Philippe Diaz

Nina Isoherranen

Nicolas Guilloteau

The present disclosure is generally directed to compositions and methods for treating diseases that are ameliorated by the inhibition of CYP26 mediated retinoic acid metabolism. The compositions comprise compounds of formula (I). A repreid50000060307390 IB/345 nullsents aryl optionally substituted with one, two, three, or four groups that are each independently halogen, cyano, nitro, Calkyl, Chaloalkyl, &#x2014;NH, &#x2014;NH(C-Calkyl), &#x2014;N(C-Calkyl), &#x2014;OH, C-Calkoxy, and C-Chaloalkoxy; X is a bond, &#x2014;CH&#x2014;, &#x2014;CHR&#x2014;, &#x2014;C&#x2550;CHR&#x2014;, &#x2014;NR&#x2014;, &#x2014;N&#x2550;O&#x2014;R&#x2014;, &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;C(O)&#x2014;, or &#x2014;C(NR)&#x2014;, or X is of formula (a), (b) or (c), wherein each n is independently 1, 2, or 3; each Ris independently hydrogen or Calkyl; Ris independently hydrogen, Calkyl, or &#x2014;OR, where Ris selected from the group consisting of hydrogen, Calkyl, Calkenyl, CalkynyL Ccycloalkyl, heterocyclyl, aryl, arylCalkyl, heteroaryl, or heteroarylCalkyl; Y is Calkylene, Calkenylene, or Calkylylene moiety. 

Growing community of inventors

Seattle, WA, United States of America

Brian Buttrick